Skip to main content

Advertisement

SpringerLink
Log in

Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation

  • Letter to the Editor
  • Published:
Annals of Hematology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Gooley TA, Chien JW, Pergam SA, Hingorani S, Sorror ML, Boeckh M, Martin PJ, Sandmaier BM, Marr KA, Appelbaum FR, Storb R, McDonald GB (2010) Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med 363(22):2091–2101. https://doi.org/10.1056/NEJMoa1004383

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD, Maziarz RT, Cortes J, Kalaycio ME, Horowitz MM (2013) Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). Blood 122(11):1974–1982. https://doi.org/10.1182/blood-2013-04-496778

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J (2012) Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. Blood 119(17):3908–3916. https://doi.org/10.1182/blood-2011-09-381699

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Fuji S, Kanda J, Kato S, Ikegame K, Morishima S, Miyamoto T et al (2014) Impact of HLA allele mismatch on the clinical outcome in serologically matched related hematopoietic SCT. Bone Marrow Transplant 49(9):1187–1192. https://doi.org/10.1038/bmt.2014.141

    Article  CAS  PubMed  Google Scholar 

  5. Ho VT, Kim HT, Liney D, Milford E, Gribben J, Cutler C, Lee SJ, Antin JH, Soiffer RJ, Alyea EP (2006) HLA-C mismatch is associated with inferior survival after unrelated donor non-myeloablative hematopoietic stem cell transplantation. Bone Marrow Transplant 37(9):845–850. https://doi.org/10.1038/sj.bmt.1705315

    Article  CAS  PubMed  Google Scholar 

  6. Martin PJ, Schoch G, Fisher L, Byers V, Appelbaum FR, McDonald GB, Storb R, Hansen JA (1991) A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 77(8):1821–1828

    CAS  PubMed  Google Scholar 

  7. Storb R, Deeg HJ, Farewell V, Doney K, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Hansen J (1986) Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease. Blood 68(1):119–125

    CAS  PubMed  Google Scholar 

  8. Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W, Buckner CD, Clift R, Doney K, Farewell V, Hansen J, Hill R, Lum L, Martin P, McGuffin R, Sanders J, Stewart P, Sullivan K, Witherspoon R, Yee G, Thomas ED (1986) Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 314(12):729–735. https://doi.org/10.1056/NEJM198603203141201

    Article  CAS  PubMed  Google Scholar 

  9. Heitman J, Movva NR, Hall MN (1991) Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253(5022):905–909

    Article  CAS  PubMed  Google Scholar 

  10. Thomson AW, Turnquist HR, Raimondi G (2009) Immunoregulatory functions of mTOR inhibition. Nat Rev Immunol 9(5):324–337. https://doi.org/10.1038/nri2546

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Perl A (2016) Activation of mTOR (mechanistic target of rapamycin) in rheumatic diseases. Nat Rev Rheumatol 12(3):169–182. https://doi.org/10.1038/nrrheum.2015.172

    Article  CAS  PubMed  Google Scholar 

  12. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P et al (1999) Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 67(7):1036–1042

    Article  CAS  PubMed  Google Scholar 

  13. Benito AI, Furlong T, Martin PJ, Anasetti C, Appelbaum FR, Doney K, Nash RA, Papayannopoulou T, Storb R, Sullivan KM, Witherspoon R, Deeg HJ (2001) Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 72(12):1924–1929

    Article  CAS  PubMed  Google Scholar 

  14. Stepkowski SM, Tian L, Napoli KL, Ghobrial R, Wang ME, Chou TC et al (1997) Synergistic mechanisms by which sirolimus and cyclosporin inhibit rat heart and kidney allograft rejection. Clin Exp Immunol 108(1):63–68

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Chen H, Qi S, Xu D, Fitzsimmons WE, Bekersky I, Sehgal SN, Daloze P (1998) Combined effect of rapamycin and FK 506 in prolongation of small bowel graft survival in the mouse. Transplant Proc 30(6):2579–2581

    Article  CAS  PubMed  Google Scholar 

  16. Antin JH, Kim HT, Cutler C, Ho VT, Lee SJ, Miklos DB, Hochberg EP, Wu CJ, Alyea EP, Soiffer RJ (2003) Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 102(5):1601–1605. https://doi.org/10.1182/blood-2003-02-0489

    Article  CAS  PubMed  Google Scholar 

  17. Filipovich AH, Weisdorf D, Pavletic S, Socie G, Wingard JR, Lee SJ, Martin P, Chien J, Przepiorka D, Couriel D, Cowen EW, Dinndorf P, Farrell A, Hartzman R, Henslee-Downey J, Jacobsohn D, McDonald G, Mittleman B, Rizzo JD, Robinson M, Schubert M, Schultz K, Shulman H, Turner M, Vogelsang G, Flowers MED (2005) National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant 11(12):945–956. https://doi.org/10.1016/j.bbmt.2005.09.004

    Article  PubMed  Google Scholar 

  18. Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, Ferrara J, Soiffer R, Giralt S (2005) Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 11(8):571–575. https://doi.org/10.1016/j.bbmt.2005.06.001

    Article  PubMed  Google Scholar 

  19. Kharfan-Dabaja MA, Parody R, Perkins J, Lopez-Godino O, Lopez-Corral L, Vazquez L, Caballero D, Falantes J, Shapiro J, Ortí G, Barba P, Valcárcel D, Esquirol A, Martino R, Piñana JL, Solano C, Tsalatsanis A, Pidala J, Anasetti C, Perez-Simón JA (2017) Tacrolimus plus sirolimus with or without ATG as GVHD prophylaxis in HLA-mismatched unrelated donor allogeneic stem cell transplantation. Bone Marrow Transplant 52(3):438–444. https://doi.org/10.1038/bmt.2016.269

    Article  CAS  PubMed  Google Scholar 

  20. Lindner S, Berg T, Riemann J, Ajib S, Jedlickova Z, Gueller S, Lang F, Martin H, Serve H, Bacigalupo A, Bug G (2016) Mismatched unrelated hematopoietic stem cell transplantation with post-transplant cyclophosphamide for high-risk acute myeloid leukemia. Ann Hematol 95(6):1023–1025. https://doi.org/10.1007/s00277-016-2652-8

    Article  PubMed  Google Scholar 

  21. Kasamon YL, Ambinder RF, Fuchs EJ, Zahurak M, Rosner GL, Bolaños-Meade J, Levis MJ, Gladstone DE, Huff CA, Swinnen LJ, Matsui WH, Borrello I, Brodsky RA, Jones RJ, Luznik L (2017) Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. Blood Advances 1:288–292

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Section of Hematology/Department of Internal Medicine and Yale Cancer Center, Smilow Cancer Hospital at Yale-New Haven, Yale University School of Medicine, New Haven, USA

    Tae Kon Kim, Maximilian Stahl, Iris Isufi, Francine Foss, Amer M. Zeidan & Stuart Seropian

  2. Department of Public Health, Yale University, New Haven, USA

    Michelle DeVeaux & Daniel Zelterman

  3. Rutgers Cancer Institute of New Jersey, New Brunswick, USA

    Dennis Cooper

  4. University of Pittsburgh School of Medicine, Division of Hematology and Oncology, Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, USA

    Warren Shlomchik

Authors
  1. Tae Kon Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michelle DeVeaux
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maximilian Stahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sarah Perreault
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Iris Isufi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Dennis Cooper
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Francine Foss
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Warren Shlomchik
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Daniel Zelterman
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Amer M. Zeidan
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Stuart Seropian
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stuart Seropian.

Ethics declarations

Ethical standards statement

This study was in accordance with the ethical standards of the responsible institutional committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2008.

Informed consent

Informed consent was obtained from all patients for being included in the study.

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, T.K., DeVeaux, M., Stahl, M. et al. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation. Ann Hematol 98, 237–240 (2019). https://doi.org/10.1007/s00277-018-3427-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-018-3427-1

Search

Navigation